AP2015008740A0 - Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof - Google Patents
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereofInfo
- Publication number
- AP2015008740A0 AP2015008740A0 AP2015008740A AP2015008740A AP2015008740A0 AP 2015008740 A0 AP2015008740 A0 AP 2015008740A0 AP 2015008740 A AP2015008740 A AP 2015008740A AP 2015008740 A AP2015008740 A AP 2015008740A AP 2015008740 A0 AP2015008740 A0 AP 2015008740A0
- Authority
- AP
- ARIPO
- Prior art keywords
- immunoreactive
- virus
- express
- effector cells
- immune effector
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012642 immune effector Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361783195P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/025491 WO2014159940A1 (en) | 2013-03-14 | 2014-03-13 | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2015008740A0 true AP2015008740A0 (en) | 2015-09-30 |
Family
ID=51625295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2015008740A AP2015008740A0 (en) | 2013-03-14 | 2014-03-13 | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
Country Status (25)
Country | Link |
---|---|
US (4) | US9908938B2 (pt) |
EP (2) | EP3839044A1 (pt) |
JP (3) | JP6676521B2 (pt) |
CN (2) | CN105189561B (pt) |
AP (1) | AP2015008740A0 (pt) |
AU (2) | AU2014244286B2 (pt) |
BR (1) | BR112015022790A8 (pt) |
CA (1) | CA2906566A1 (pt) |
CY (1) | CY1124570T1 (pt) |
DK (1) | DK2968520T3 (pt) |
ES (1) | ES2882183T3 (pt) |
HK (1) | HK1219876A1 (pt) |
HR (1) | HRP20211212T1 (pt) |
HU (1) | HUE055845T2 (pt) |
IL (2) | IL241487B (pt) |
LT (1) | LT2968520T (pt) |
MX (2) | MX2015012709A (pt) |
PL (1) | PL2968520T3 (pt) |
PT (1) | PT2968520T (pt) |
RS (1) | RS62304B1 (pt) |
RU (2) | RU2020115527A (pt) |
SG (2) | SG10201705245TA (pt) |
SI (1) | SI2968520T1 (pt) |
WO (1) | WO2014159940A1 (pt) |
ZA (1) | ZA201506658B (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
PL2968520T3 (pl) | 2013-03-14 | 2022-01-03 | Macrogenics, Inc. | Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego |
UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
TWI652279B (zh) | 2013-11-11 | 2019-03-01 | 中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
CN107108721B (zh) | 2014-09-29 | 2021-09-07 | 杜克大学 | 包含hiv-1包膜靶向臂的双特异性分子 |
WO2016149698A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies) |
CA2979708A1 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
WO2016149710A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
WO2016149695A1 (en) | 2015-03-19 | 2016-09-22 | Duke University | HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES) |
US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
CR20180318A (es) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas |
SG10201913326UA (en) | 2016-06-07 | 2020-02-27 | Macrogenics Inc | Combination therapy |
EP3313174A4 (en) | 2016-07-14 | 2019-02-27 | Rolane Christian Grinnell | PORTABLE PET FEEDER AND SUPPLY MEMORY DEVICE |
SG10202100268RA (en) | 2016-08-13 | 2021-02-25 | United Biopharma Inc | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
EP3579848A4 (en) | 2017-02-08 | 2021-03-03 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR ACTIVATING NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES FOR TREATING CANCER |
AU2018220736A1 (en) | 2017-02-20 | 2019-09-05 | Dragonfly Therapeutics, Inc. | Proteins binding HER2, NKG2D and CD16 |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
CN108728464A (zh) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | 一种表达抗hiv双特异性抗体的微环dna载体及其制备方法和应用 |
CN108728465A (zh) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用 |
CN108728463A (zh) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | 一种表达IgG抗体的微环DNA载体及其制备方法和应用 |
CN110831965B (zh) | 2017-06-21 | 2023-03-07 | 吉利德科学公司 | 靶向hiv gp120和cd3的多特异性抗体 |
CA3069842A1 (en) * | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
CL2020000098A1 (es) * | 2017-07-14 | 2020-05-29 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada. |
CN109384848A (zh) * | 2017-08-10 | 2019-02-26 | 深圳市雅臣智能生物工程有限公司 | 抗人乳头瘤病毒和抗cd人源化的双靶向抗体及其组合物、制备方法和应用 |
WO2019033043A2 (en) * | 2017-08-11 | 2019-02-14 | Genentech, Inc. | ANTI-CD8 ANTIBODIES AND USES THEREOF |
RU2020122822A (ru) | 2017-12-12 | 2022-01-13 | Макродженикс, Инк. | Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний |
CN112368012A (zh) | 2018-02-08 | 2021-02-12 | 蜻蜓疗法股份有限公司 | 靶向nkg2d受体的抗体可变结构域 |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
AU2019269383A1 (en) * | 2018-05-18 | 2020-12-10 | Duke University | Optimized GP41-binding molecules and uses thereof |
WO2020051248A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
CN109734810A (zh) * | 2019-01-24 | 2019-05-10 | 深圳市雅臣智能生物工程有限公司 | 抗非洲猪瘟病毒和cd双靶标猪源化抗体、制备法和应用 |
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
US20240093158A1 (en) * | 2019-10-10 | 2024-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic viruses that express multi-specific immune cell engagers |
JOP20220150A1 (ar) * | 2019-12-18 | 2023-01-30 | Janssen Biotech Inc | مواد وطرق للاستهداف البيولوجي في الجسم الحي |
CN113088495A (zh) * | 2020-01-09 | 2021-07-09 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
KR20230054456A (ko) * | 2020-08-25 | 2023-04-24 | 길리애드 사이언시즈, 인코포레이티드 | Hiv를 표적으로 하는 다중특이적 항원 결합 분자 및 이의 사용 방법 |
TW202216754A (zh) * | 2020-08-25 | 2022-05-01 | 美商賽特免疫治療公司 | 雙特異性抗體car細胞免疫療法 |
US20230331844A1 (en) * | 2020-10-12 | 2023-10-19 | Greffex, Inc. | Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses |
JP2023544890A (ja) | 2020-10-13 | 2023-10-25 | ヤンセン バイオテツク,インコーポレーテツド | 分化抗原群iv及び/又はviiiを調節するための生物工学的に作製されたt細胞媒介免疫、材料及び他の方法 |
WO2022093694A1 (en) * | 2020-10-26 | 2022-05-05 | A2 Biotherapeutics, Inc. | Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof |
WO2023227018A1 (zh) * | 2022-05-25 | 2023-11-30 | 羿尊生物医药(浙江)有限公司 | 靶向细胞膜受体蛋白的融合蛋白及其应用 |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (pt) | 1974-03-08 | 1982-06-04 | ||
US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4752601A (en) | 1983-08-12 | 1988-06-21 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin FC receptors |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5985599A (en) | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
EP0359096B1 (en) | 1988-09-15 | 1997-11-05 | The Trustees Of Columbia University In The City Of New York | Antibodies having modified carbohydrate content and methods of preparation and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
GB8916400D0 (en) | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5364930A (en) | 1990-10-16 | 1994-11-15 | Northwestern University | Synthetic C1q peptide fragments |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
PT682710E (pt) | 1993-02-10 | 2004-03-31 | Unilever Nv | Processo de isolamento utilizando proteinas imobilizadas com capacidades de ligacao especificas |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
DE69434520T3 (de) | 1993-07-30 | 2009-10-15 | Affymax, Inc., Palo Alto | Biotinylierung von proteinen |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
ATE204300T1 (de) | 1994-05-13 | 2001-09-15 | Biovation Ltd | Zielzellen-bindende chimäre peptide |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
US6025485A (en) | 1997-02-14 | 2000-02-15 | Arcaris, Inc. | Methods and compositions for peptide libraries displayed on light-emitting scaffolds |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
DE69840723D1 (de) | 1997-02-11 | 2009-05-20 | Immunomedics Inc | Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DE69830901T2 (de) * | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
JP2002505086A (ja) | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | 抗体ベースの融合タンパク質の循環半減期の増強 |
US6455263B2 (en) | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
SE9802213D0 (sv) | 1998-06-18 | 1998-06-18 | Amersham Pharm Biotech Ab | A method for the removal/purification of serum albumins and means for use in the method |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
DE19937264A1 (de) | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶-Antikörper-Konstrukte |
AU2001233277B2 (en) * | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
JP2004500108A (ja) | 2000-03-24 | 2004-01-08 | マイクロメット アーゲー | Nkg2dレセプター複合体のエピトープへの結合部位を含む多機能ポリペプチド |
AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20030199671A1 (en) | 2001-04-18 | 2003-10-23 | Rondon Isaac Jesus | Binding molecules for Fc-region polypeptides |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
EP2316485A1 (en) | 2001-10-12 | 2011-05-04 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
DE60237704D1 (de) | 2001-10-16 | 2010-10-28 | Government Of The Us Secretary | Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20050142539A1 (en) | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
CA2484182A1 (en) | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
CA2490009A1 (en) | 2002-06-21 | 2003-12-31 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
BRPI0314814C1 (pt) | 2002-09-27 | 2021-07-27 | Xencor Inc | anticorpo compreendendo uma variante de fc |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2272533A1 (en) | 2003-01-13 | 2011-01-12 | MacroGenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
JP5026072B2 (ja) | 2003-07-01 | 2012-09-12 | イミューノメディクス、インコーポレイテッド | 二重特異性抗体の多価キャリヤー |
DE10346627A1 (de) | 2003-10-08 | 2005-05-19 | Weiss, Stefan, PD Dr. | Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
DE602005015542D1 (de) | 2004-01-12 | 2009-09-03 | Applied Molecular Evolution | Varianten der fc-region |
WO2005097175A2 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
DE05733048T1 (de) | 2004-04-06 | 2007-05-10 | Affibody Ab | Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung |
MXPA06011796A (es) | 2004-04-16 | 2007-05-07 | Macrogenics Inc | Anticuerpos especificos de fc(riib y metodos para el uso de los mismos. |
AU2005244058B2 (en) | 2004-05-10 | 2011-07-28 | Macrogenics, Inc. | Humanized FcgammaRIIB specific antibodies and methods of use thereof |
US7432419B2 (en) | 2004-05-14 | 2008-10-07 | Los Alamos National Security, Llc | Compositions and methods for the treatment of Pierce's disease |
CA2568952C (en) | 2004-06-18 | 2019-05-21 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
EA012464B1 (ru) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
WO2006044410A2 (en) * | 2004-10-14 | 2006-04-27 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
US20060193849A1 (en) | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
EP2336174B8 (en) | 2005-03-14 | 2015-09-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Human monoclonal antibodies against Hendra and Nipah viruses |
CA2605024C (en) * | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2008157379A2 (en) * | 2007-06-21 | 2008-12-24 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
SI2573114T1 (sl) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo |
AU2006301492B2 (en) * | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
JP5427027B2 (ja) * | 2006-05-03 | 2014-02-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト | Cd40アゴニスト抗体/i型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 |
WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
SI2125792T1 (sl) | 2007-02-19 | 2011-03-31 | Glaxosmithkline Llc | Purinski derivati kot imunomodulatorji |
EP2209810A1 (en) | 2007-10-15 | 2010-07-28 | King's College London | Viral therapeutic |
JP2011502163A (ja) | 2007-10-31 | 2011-01-20 | ザ スクリプス リサーチ インスティテュート | 持続性ウイルス感染を治療するための併用療法 |
US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
JP2011516423A (ja) | 2008-03-28 | 2011-05-26 | シー レーン バイオテクノロジーズ, エルエルシー | ウイルス抗原に対する中和分子 |
US20100040601A1 (en) | 2008-06-10 | 2010-02-18 | Cantin Edouard M | Compositions and methods for treating herpes simplex virus infections and related diseases |
SI2786762T1 (sl) | 2008-12-19 | 2019-07-31 | Macrogenics, Inc. | Kovalentna diatelesa in njihove uporabe |
US8211866B2 (en) | 2009-01-14 | 2012-07-03 | Children's Research Institute, Children's National Medical Center | Methods and compositions for treating HIV infection |
EP2406387A4 (en) | 2009-03-09 | 2013-04-17 | Tvax Biomedical I Llc | CELL IMMUNOTHERAPY FOR INFECTION DISEASES |
US20110033389A1 (en) | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
DK2438087T3 (en) | 2009-06-05 | 2017-08-28 | Ablynx Nv | TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS |
AU2010265933B2 (en) | 2009-06-26 | 2015-05-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
US8568719B2 (en) | 2009-08-13 | 2013-10-29 | Crucell Holland B.V. | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US8999398B2 (en) | 2009-11-06 | 2015-04-07 | Transtarget Inc. | Polyclonal bispecific antibody compositions and method of use |
US8663950B2 (en) | 2010-01-11 | 2014-03-04 | Arizona Board Of Regents | Production of a monoclonal antibody therapeutic against west nile virus in plants |
ES2617777T5 (es) * | 2010-04-23 | 2022-10-13 | Hoffmann La Roche | Producción de proteínas heteromultiméricas |
CA2807127C (en) * | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
PT3556396T (pt) | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) |
CA2825064C (en) * | 2011-02-04 | 2022-08-30 | Genentech, Inc. | Fc variants and methods for their production |
SG195072A1 (en) * | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
KR102030531B1 (ko) | 2011-05-21 | 2019-10-10 | 마크로제닉스, 인크. | 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도 |
WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
US9879068B2 (en) | 2012-06-21 | 2018-01-30 | California Institute Of Technology | Antibodies targeting HIV escape mutants |
US20150239961A1 (en) | 2012-09-26 | 2015-08-27 | Duke University | Adcc-mediating antibodies, combinations and uses thereof |
PL2968520T3 (pl) | 2013-03-14 | 2022-01-03 | Macrogenics, Inc. | Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego |
-
2014
- 2014-03-13 PL PL14776214T patent/PL2968520T3/pl unknown
- 2014-03-13 ES ES14776214T patent/ES2882183T3/es active Active
- 2014-03-13 AP AP2015008740A patent/AP2015008740A0/xx unknown
- 2014-03-13 CN CN201480025460.8A patent/CN105189561B/zh not_active Expired - Fee Related
- 2014-03-13 DK DK14776214.0T patent/DK2968520T3/da active
- 2014-03-13 RS RS20210957A patent/RS62304B1/sr unknown
- 2014-03-13 EP EP20217972.7A patent/EP3839044A1/en active Pending
- 2014-03-13 BR BR112015022790A patent/BR112015022790A8/pt active Search and Examination
- 2014-03-13 CN CN202010439230.3A patent/CN111925437A/zh active Pending
- 2014-03-13 US US14/775,041 patent/US9908938B2/en active Active
- 2014-03-13 RU RU2020115527A patent/RU2020115527A/ru unknown
- 2014-03-13 JP JP2016501861A patent/JP6676521B2/ja not_active Expired - Fee Related
- 2014-03-13 CA CA2906566A patent/CA2906566A1/en active Pending
- 2014-03-13 EP EP14776214.0A patent/EP2968520B1/en active Active
- 2014-03-13 SI SI201431859T patent/SI2968520T1/sl unknown
- 2014-03-13 AU AU2014244286A patent/AU2014244286B2/en not_active Ceased
- 2014-03-13 PT PT147762140T patent/PT2968520T/pt unknown
- 2014-03-13 SG SG10201705245TA patent/SG10201705245TA/en unknown
- 2014-03-13 LT LTEP14776214.0T patent/LT2968520T/lt unknown
- 2014-03-13 MX MX2015012709A patent/MX2015012709A/es unknown
- 2014-03-13 WO PCT/US2014/025491 patent/WO2014159940A1/en active Application Filing
- 2014-03-13 SG SG11201507424WA patent/SG11201507424WA/en unknown
- 2014-03-13 RU RU2015143457A patent/RU2721707C2/ru not_active Application Discontinuation
- 2014-03-13 HU HUE14776214A patent/HUE055845T2/hu unknown
-
2015
- 2015-09-09 ZA ZA2015/06658A patent/ZA201506658B/en unknown
- 2015-09-10 IL IL241487A patent/IL241487B/en active IP Right Grant
- 2015-09-11 MX MX2021000435A patent/MX2021000435A/es unknown
-
2016
- 2016-07-06 HK HK16107893.5A patent/HK1219876A1/zh unknown
-
2018
- 2018-01-24 US US15/879,056 patent/US10730947B2/en active Active
-
2019
- 2019-02-08 AU AU2019200912A patent/AU2019200912B2/en not_active Ceased
- 2019-12-10 JP JP2019222992A patent/JP6979447B2/ja active Active
-
2020
- 2020-03-29 IL IL273666A patent/IL273666B/en active IP Right Grant
- 2020-06-22 US US16/908,185 patent/US11421031B2/en active Active
-
2021
- 2021-07-27 HR HRP20211212TT patent/HRP20211212T1/hr unknown
- 2021-08-11 CY CY20211100722T patent/CY1124570T1/el unknown
- 2021-09-22 JP JP2021154658A patent/JP2022000044A/ja active Pending
-
2022
- 2022-07-14 US US17/812,492 patent/US20230167178A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273666B (en) | Bispecific molecules immunoreactive with effector cells of the immune system that express a receptor from Actab and an antigen expressed by a virus-infected cell and their uses | |
EP3057991B8 (en) | Chimeric antigen receptor t cell switches and uses thereof | |
DK2992020T3 (da) | Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller | |
IL238559B (en) | Antibodies against ceacam5 and their use | |
EP2832856A4 (en) | ANTI-LAMP5 ANTIBODIES AND USE THEREOF | |
EP3021868A4 (en) | Antibodies against chikungunya virus and uses thereof | |
EP2975119A4 (en) | CELL STRAIN HAVING INCREASED VIRUS PRODUCTION CAPACITY AND METHOD FOR PRODUCING THE SAME | |
ZA201407309B (en) | Antigens and antigen combinations | |
HK1210182A1 (en) | Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr) | |
EP2961427A4 (en) | HIV ANTIGENS AND ANTIBODIES AGAINST HIV ANTIGENS | |
EP2868665A4 (en) | PEPTIDE EPITOPIC PUHI26 OF LYMPHOCYTES B DIRECTED AGAINST HEPATITIS C VIRUS AND ITS APPLICATIONS | |
TH1501005500A (th) | ไบสเปซิฟิกโมเลกุล (bispecific molecules) ที่ไวต่อปฏิกิริยาทางภูมิคุ้มกัน กับอิมมูนเอฟเฟคเตอร์เซลล์ที่มีการแสดงออกของรีเซพเตอร์ที่แสดงการออกฤทธิ์ และแอนติเจนที่ถูกแสดงออกโดยเซลล์ที่ถูกติดเชื้อโดยไวรัสและการใช้ของมัน | |
AU2013903812A0 (en) | Genetically stable oncolytic virus | |
GB201207383D0 (en) | Antigens and antigen combinations | |
GB201207385D0 (en) | Antigens and antigen combinations | |
AU2012904294A0 (en) | Genetically stable oncolytic virus |